Get the Stockscreener App
144.86
0.48%
0.695
Neurocrine Biosciences Inc stock is traded at $144.86, with a volume of 642.91K.
It is up +0.48% in the last 24 hours and up +5.56% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$144.16
Open:
$142.99
24h Volume:
642.91K
Relative Volume:
0.72
Market Cap:
$14.37B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
49.11
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-4.93%
1M Performance:
+5.56%
6M Performance:
+21.96%
1Y Performance:
+17.89%
1-Day Range:
$142.99
$146.38
1-Week Range:
$142.99
$154.10
52-Week Range:
$84.23
$157.67
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
144.86 | 14.37B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfolios2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Why Neurocrine Biosciences Inc. stock remains resilientPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investors2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionEarnings Miss & Community Driven Trade Alerts - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Is Neurocrine Biosciences Inc. stock trading near support levelsJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusTrade Volume Summary & Consistent Profit Alerts - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changesWeekly Profit Report & Consistent Return Strategy Ideas - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthTake Profit & Risk Controlled Daily Trade Plans - newser.com
Measuring Neurocrine Biosciences Inc.’s beta against major indicesPortfolio Risk Summary & Daily Stock Trend Watchlist - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s futureJobs Report & Smart Swing Trading Alerts - newser.com
How to build a dashboard for Neurocrine Biosciences Inc. stockWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance
What analysts say about Neurocrine Biosciences Inc stockPrice Volatility Patterns & Small Budget Growth - earlytimes.in
Neurocrine Biosciences to Present at Upcoming Investor Conferences - Your Wyoming Link
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News - Yahoo Finance
What analysts say about Neurocrine Biosciences Inc NB3 stockSector Performance Review & Free Turn Volatility To Profit - earlytimes.in
Neurocrine’s depression candidate fails mid-stage study but analysis continues - The Pharma Letter
Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal - simplywall.st
What valuation multiples suggest for Neurocrine Biosciences Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression - MedCity News
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
Neurocrine’s Depression Drug Misses In Phase II - Citeline News & Insights
Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus
Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study - MarketScreener
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 - Investing.com Nigeria
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 By Investing.com - Investing.com South Africa
Neurocrine chalks up a depression drug failure - BioPharma Dive
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):